SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its ongoing development, transparency, and dedicated team. Token burns are anticipated as watcher counts increase, and community members are excited about the upcoming airdrop details. The focus remains on long-term growth, with some envisioning Brokecoin as a leading altcoin.

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending amid community discussions around a potential breakout and anticipation for news related to its partnership with Nvidia ($NVDA). Some traders speculate about a possible acquisition, while others are focused on insider trading activity and the impact of the new CEO, Chris Allexandre, on the company's future direction in AI data centers.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr Network ($ANKR.X) is trending amidst mixed community sentiment, with some touting its infrastructure role in Web3 and the potential of its new L1 Neura blockchain for developers, while others express strong dissatisfaction, labeling it a long-term scam and criticizing its price performance compared to other crypto assets. The core debate revolves around the token's utility and the team's ability to deliver tangible value for holders versus its promise as a foundational element for the decentralized web. Discussions also involve broader themes around infrastructure versus hype-driven crypto investments.

Pump.fun

$PUMP.X is trending as traders discuss its potential, recent website updates, and community takeover of creator rewards, driving bullish sentiment. Conversations revolve around potential breakout points, with community members calling for it to reach penny status. The coin is associated with the meme coin launchpad Pump.fun on the Solana network.

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending as community members highlight its strong ties to the Injective ecosystem and anticipate significant gains. The conversation is driven by Injective's increasing traction and potential ETF, with many believing $NONJA.X offers leveraged exposure to $INJ's growth. Community members emphasize $NONJA.X's unique features, such as its strong community, burned liquidity, and potential for high returns.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to concerns about production timelines for their Gravity SUV and the overall company's profitability, reflected in negative sentiment from some investors. Despite a recent commercial spot during an NFL game and news of accelerated Gravity SUV production, some community members express skepticism about Lucid's financial future and the effectiveness of the reverse stock split. Discussions also involve potential future funding from Saudi PIF and comparisons to other EV manufacturers like Tesla and Rivian.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA.X) is trending amid anticipation for its mainnet launch and excitement surrounding its potential to revolutionize traditional finance. Community members highlight Keeta's anchor technology and partnerships as key drivers for unifying blockchains. The recent listing on exchanges like Coinbase is also fueling positive sentiment, with some suggesting it will replace other blockchains.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending as investors digest mixed signals, including commentary around tariffs and a potential shift towards energy project ownership. Community members are actively debating the impact of government policies and comparing CSIQ's valuation to peers. Bullish sentiment highlights the company's potential in a growing solar market, while bears express concern over debt and profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?

Blueprint Medicines came under pressure from Wall Street on Monday after at least six brokerages downgraded the stock following news of its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sanofi-to-buy-blueprint-medicines-for-up-to-9.5-billion/chkoCYnRbHc">$9.1 billion acquisition</a> by French pharmaceutical giant Sanofi.The stock closed at $127.79 on Monday, up 26.1% for the day. After-hours trading showed a slight decline of 0.1% to $127.67.TD Cowen analyst Marc Frahm lowered the stock rating to ‘Hold’ from ‘Buy’ and established a price target of $130 based on the acquisition terms.&nbsp;JPMorgan reduced its rating to ‘Neutral’ from ‘Overweight’ and adjusted its target price to $129 from $130.Wolfe Research reduced Blueprint's rating to ‘Peer Perform’ from ‘Outperform’ by noting that the deal values Blueprint at $129 per share.&nbsp;Oppenheimer lowered its stock rating to ‘Perform’ from ‘Outperform,’ while describing the agreement as a “solid outcome for shareholders.”Scotiabank reduced its stock rating to ‘Sector Perform’ from ‘Outperform,’ while establishing a target price of $135.&nbsp;Wedbush assigned a $129 target after downgrading Blueprint to ‘Neutral’, while Needham downgraded it to ‘Hold.’Blueprint Medicines shareholders will receive one non-tradeable contingent value right (CVR), entitling them to two potential milestone payments of $2 and $4 per CVR, contingent on&nbsp;achieving future development and regulatory milestones for BLU-808.BLU-808 is an investigational oral inhibitor targeting wild-type KIT, which plays a role in mast cell activation involved in inflammatory diseases, including chronic urticaria.Including these potential payments, the total equity value of the Sanofi acquisition rises to approximately $9.5 billion on a fully diluted basis.Sanofi CEO Paul Hudson said this acquisition moves their rare and immunology portfolios forward.Sanofi’s earnings and gross margin will benefit from the transaction after 2026, while the company’s financial guidance for 2025 remains unaffected.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user described the price movement as a positive surprise, reporting a roughly 30% gain on their investment,&nbsp;noting this was better than recent returns on SpringWorks Therapeutics, but lower than several earlier buyouts this year.&nbsp;<stembedurl>https://stocktwits.com/Jackie_O_/message/616535057</stembedurl>Another user said that increased European pharma purchases of U.S. companies might be a strategy to gain favor with the Trump administration.<stembedurl>https://stocktwits.com/ajmore/message/616481051</stembedurl>Blueprint Medicines’&nbsp;stock has risen 46.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Blueprint Medicines company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Blueprint Medicines Stock  Lands Several Downgrades After Sanofi’s Buyout Deal, But Retail Bulls Keep The Faith

Analysts revised price targets near the deal’s $129-per-share valuation.

Equity

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines 

Shares of Blueprint Medicines Corporation (BPMC) traded 26% higher in pre-market on Monday after French pharmaceutical company Sanofi (SNY) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-02-05-00-00-3091541">announced</a> that it would acquire Blueprint in a bid to expand its rare immunological disease portfolio.Under the terms of the deal, Sanofi will pay $129 per share in cash at closing, representing an equity value of approximately $9.1 billion.The upfront purchase price represents a 27% premium to Blueprint’s closing price on Friday of $101.35.In addition, Blueprint shareholders will receive one non-tradable contingent value right (CVR), which will entitle them to receive two potential milestone payments of $2 and $4 per CVR for the achievement of future milestones for BLU-808, an investigational therapy with the potential to treat a broad range of diseases in immunology.The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis, Sanofi said. The firm added that it expects the transaction to be completed in the third quarter of 2025.The acquisition includes Ayvakit or Ayvakyt (Avapritinib), the only approved medicine for rare immunology diseases, advanced and indolent systemic mastocytosis (ASM &amp; ISM), in addition to Elenestinib, an investigational medicine for systemic mastocytosis, as well as BLU-808.Sanofi CEO Paul Hudson said that the company retains a “sizeable capacity” for further acquisitions. The firm expects the Blueprint acquisition not to have a significant impact on its financial guidance for 2025 but to be immediately accretive to gross margin and to business operating income and EPS after 2026.Last month, Sanofi said it is looking to invest at least $20 billion in the U.S. through 2030. The company also announced it would acquire U.S.-based Vigil Neuroscience, Inc. (VIGL) for about $470 million soon after.On Stocktwits, retail sentiment around Blueprint Medicines Corporation jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_8_06_38_AM_png_dab4b84360.webp" alt="BPMC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>BPMC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, retail sentiment around Sanofi stayed unmoved within the ‘bullish’ territory while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:630/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_8_14_54_AM_png_d728df50b2.webp" alt="SNY's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits" width="630" height="65"><figcaption>SNY's Sentiment Meter and Message Volume as of 8:15 a.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes U.S. pharmaceutical companies will receive acquisition offers from their European counterparts.<stembedurl>https://stocktwits.com/ajmore/message/616481051</stembedurl>While <a href="https://stocktwits.com/symbol/BPMC">BPMC stock</a> is up by about 16% this year, <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> is up by over 2%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/microsoft-commits-400-million-to-boost-swiss-ai-cloud-ecosystem/chkoUr7RbHb">Microsoft Commits $400M To Boost Swiss AI, Cloud Ecosystem: Retail Mood Stays ‘Bearish’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies

Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results PR Newswire CAMBRIDGE, Mass., Feb. 13, 2025 -- Achieved...

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on...

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth PR Newswire CAMBRIDGE...

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass...

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting Blueprint Medicines' Continued Leadership in Redefining...

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit's significant growth, 2024 revenue forecast, and potential strategic opportunities.

 Latest Ratings for BPMC...

Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

BPMC
Blueprint Medicines Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BPMC News

BPMC Blueprint Medicines Corp